Intuitive Surgical Inc

Most Recent

  • uploads///black and white blood pressure blood pressure monitor
    Company & Industry Overviews

    What Are Intuitive Surgical’s Key Growth Drivers in 2019?

    In the first quarter, Intuitive Surgical (ISRG) placed 235 da Vinci systems, a YoY (year-over-year) rise of 27.03%. However, its Systems revenue in the first quarter was $248 million, a YoY rise of 6%.

    By Margaret Patrick
  • uploads///adult career clipboard
    Healthcare

    How Are Intuitive Surgical’s Revenues Trending in 2019?

    According to its first-quarter earnings conference call, Intuitive Surgical reported a 27% YoY rise in total new system placements, while its installed base rose 13% YoY net of trade exam retirements. At the end of the first quarter, the company had an installed base of 5,110.

    By Margaret Patrick
  • uploads///Part
    Fund Managers

    Druckenmiller Was Betting on These Top Names in Q4

    Druckenmiller seemed to be positive on emerging markets, as the iShares MSCI Emerging Markets ETF (EEM) formed 3.8% of his portfolio at the end of the fourth quarter.

    By Anuradha Garg
  • uploads///TMO
    Company & Industry Overviews

    Do Analysts See Any Upside for Thermo Fisher Stock?

    Of the 17 analysts covering Thermo Fisher Scientific (TMO), 14 recommend ” buy” or a higher rating, and three recommend “hold.”

    By Kenneth Smith
  • uploads///TMO
    Company & Industry Overviews

    Thermo Fisher Scientific’s Gross Margin Trends

    In fiscal 2018 and fiscal 2019, Thermo Fisher Scientific (TMO) is expected to generate revenue of $24.08 billion and $25.19 billion, respectively, compared with revenue of $20.92 billion in fiscal 2017.

    By Kenneth Smith
  • uploads///ISRG
    Company & Industry Overviews

    How Intuitive Surgical Stock Has Performed in the Last Month

    From a low of $376.92 on January 4, Intuitive Surgical (ISRG) stock rose to a high of $581.12 on October 1.

    By Kenneth Smith
  • uploads///ISRG
    Company & Industry Overviews

    Intuitive Surgical Stock Has Seen Growth of 34% Year-to-Date

    Intuitive Surgical’s stock price rose from $364.94 at the close of market on December 29, 2017, to $489.57 on November 23, 2018.

    By Daniel Collins
  • uploads///molecule _
    Earnings Report

    How TransEnterix Has Been Performing in November

    In this series, we’ll explore TransEnterix’s financials, analyst recommendations, and valuation metrics.

    By Kenneth Smith
  • uploads///NVCR ana reco
    Earnings Report

    Gauging Analysts’ Views for NovoCure Stock

    Of the five analysts covering NovoCure (NVCR) stock in October, two have given it a “strong buy,” and three have given it a “buy.”

    By Kenneth Smith
  • uploads///ISRG RD
    Earnings Report

    How Intuitive’s Bottom Line Is Expected to Look in Q3 2018

    Intuitive Surgical’s (ISRG) cost of goods sold is expected to rise 16.82% to $265.76 million in the third quarter of 2018.

    By Kenneth Smith
  • uploads///hospital _
    Earnings Report

    What to Expect from Intuitive Surgical’s Q3 2018 Earnings

    Intuitive Surgical (ISRG) is expected to report its third-quarter earnings results on October 18.

    By Kenneth Smith
  • uploads///pulse trace _
    Company & Industry Overviews

    TransEnterix Stock Rose 5.41% after Its Corporate Update

    On October 1, TransEnterix stock closed at $5.64, which represents ~344.0% growth from its 52-week low of $1.27 on February 9.

    By Daniel Collins
  • uploads///VRAY ana reco
    Company & Industry Overviews

    What ViewRay’s Valuation Trend Indicates

    In September, of the seven analysts covering ViewRay (VRAY), six have given its stock “buy” or higher ratings, and one analyst has given it a “sell” rating.

    By Kenneth Smith
  • uploads///Danaher ana reco
    Company & Industry Overviews

    Analyzing the Performance of Danaher’s Dental Business

    Danaher Corp.’s (DHR) enterprise value is $85.21 billion, and its enterprise-value-to-revenue ratio is 4.42.

    By Kenneth Smith
  • uploads///laboratory _
    Company & Industry Overviews

    How Quest Diagnostics Is Positioned in 2018

    Quest Diagnostics generated revenues of $1.92 billion in the second quarter of 2018 as compared with $1.86 billion in the second quarter of 2017.

    By Kenneth Smith
  • uploads///TMO
    Company & Industry Overviews

    What’s the Upside Potential of Thermo Fisher Scientific Stock?

    So far in 2018, Thermo Fisher Scientific (TMO) stock has generated double-digit returns for investors.

    By Kenneth Smith
  • uploads///ISRG procedures
    Company & Industry Overviews

    A Strong Business Model Bodes Well for Intuitive Surgical

    Intuitive Surgical (ISRG) generates a major part of its revenue from the US market.

    By Kenneth Smith
  • uploads///TransEnterix
    Company & Industry Overviews

    TransEnterix Stock Saw 18% Growth in Week Ended August 24

    On August 24, TransEnterix (TRXC) stock closed at $5.37, which represents a ~6.13% growth from its prior day’s close of $5.06.

    By Daniel Collins
  • uploads///Graph
    Company & Industry Overviews

    TransEnterix Expected to Report Solid Rise in Revenues in 2018

    TransEnterix (TRXC) expects to sell three Senhance systems in Q3 2018.

    By Margaret Patrick
  • uploads///surgery _
    Company & Industry Overviews

    What Analysts Recommend for TransEnterix and Peers in August 2018

    Of the five analysts covering TransEnterix in August, one has recommended a “strong buy,” one has recommended a “buy,” and three have recommended a “hold.”

    By Margaret Patrick
  • uploads///NVCR
    Earnings Report

    Why Most Analysts Are Bullish on NovoCure

    NovoCure’s R&D expenses are expected to increase 47.06% from $9.37 million in Q2 2017 to $13.78 million in Q2 2018.

    By Kenneth Smith
  • uploads///Picture
    Consumer

    Why Goldman Sachs Thinks FB and NVIDIA Could Do Well in H2 2018

    Year-to-date through July 5, Facebook has risen 11.7% and NVIDIA has risen 24.7%

    By Sarah Sands
  • uploads///orthopedics outlook
    Company & Industry Overviews

    Stryker’s Mako Robot Sales Momentum Continues to Fuel Growth

    In 4Q17, the momentum in Stryker’s (SYK) Mako robot installations continued with total worldwide installations of 35 Mako robots.

    By Sarah Collins
  • uploads///hand _
    Company & Industry Overviews

    Johnson & Johnson Advances in Robotics Surgery with Orthotaxy

    On February 20, Johnson & Johnson (JNJ) announced the acquisition of Orthotaxy to develop its robot-assisted orthopedics surgery platform.

    By Sarah Collins
  • uploads///STOCK PRICE
    Earnings Report

    Intuitive Surgical: What’s Driving the Bull Run?

    Leading surgical robotics player Intuitive Surgical (ISRG) is trading at all-time highs. The stock has been rising, returning 98% over the past year.

    By Sarah Collins
  • uploads///procedure trend
    Earnings Report

    Intuitive Surgical’s Da Vinci Procedure Could Boost 2017 Results

    According to Intuitive Surgical’s (ISRG) preliminary 4Q17 and 2017 results posted by the company on January 10, 2018, it expects to post da Vinci procedure growth of 17% in 4Q17.

    By Sarah Collins
  • uploads///sales_estimates
    Earnings Report

    Can Intuitive Surgical Beat Analyst Estimates Again in 4Q17?

    On January 25, 2018, Intuitive Surgical (ISRG) is expected to announce its fiscal 4Q17 and fiscal 2017 earnings results. It’s expected to post strong results.

    By Sarah Collins
  • uploads///GUIDANCE
    Earnings Report

    Will Varian Medical Systems’ Sales Decline Again in 1Q18?

    According to Wall Street analysts’ estimates, Varian Medical Systems (VAR) will report revenues of $636.8 million in 1Q18, a YoY decline of 16.6%.

    By Sarah Collins
  • uploads///recommendations
    Earnings Report

    Analyst Recommendations for Varian Medical Systems before 1Q18

    Varian Medical Systems (VAR) will announce its 1Q18 earnings results on January 24, 2018. It wants to establish itself as the leading cancer management company in the world.

    By Sarah Collins
  • uploads///recommendation
    Company & Industry Overviews

    Discussing Analysts’ Latest Recommendations on VAR Stock

    Varian Medical Systems (VAR) is a better-aligned, leaner business with a strong market position after the spin-off of Varex Imaging (VREX) in January 2017.

    By Sarah Collins
  • uploads///GOP TAX BILL
    Healthcare

    How the Corporate Tax Rate Cut Could Affect R&D in the Medtech Industry

    The repeal of the tax deduction for high medical expenses may reduce the number of taxpayers opting for costly medical technologies and services.

    By Sarah Collins
  • uploads///etf performance
    Company & Industry Overviews

    How the Medical Expense Tax Deduction Affects the Healthcare Industry

    According to AARP, around 75% the population claiming these medical expense deductions from their income are 50 years or older.

    By Sarah Collins
  • uploads///analyst recommendations
    Company & Industry Overviews

    Varian’s Latest Wall Street Recommendations: Mostly ‘Hold’

    According to a recent Reuters survey, which included eight investment brokerage firms, six (or 75%) of them have recommended a “hold” for VAR stock.

    By Sarah Collins
  • uploads///GUIDANCE
    Company & Industry Overviews

    Varian’s Long-Term Growth Strategy: Will It Drive 2018 Guidance?

    Varian Medical Systems expects to see fiscal 2018 revenue growth in the range of 2%–4%. Its adjusted diluted EPS (earnings per share) for fiscal 2018 is expected to be $4.20–$4.32.

    By Sarah Collins
  • uploads///highlights
    Company & Industry Overviews

    Varian Medical Systems’ Profitability Profile

    In fiscal 4Q17, Varian Medical Systems (VAR) registered a gross profit margin of 42.3% of its total sales, representing a decline of 50 basis points.

    By Sarah Collins
  • uploads///GEOGRAPHY ONCOLOGY
    Company & Industry Overviews

    Varian’s Performance by Geography and Future Growth Potential

    Varian’s Oncology segment sales in the Americas rose 2%, whereas order growth in the region rose 1% in 4Q17.

    By Sarah Collins
  • uploads///OPERATIONAL PLANS
    Company & Industry Overviews

    Zimmer Biomet’s Plan to Revive Growth amid Supply Disruptions

    Zimmer Biomet Holdings has laid down a dual sourcing strategy to resolve production issues at its Warsaw facility.

    By Sarah Collins
  • uploads///novadaq
    Earnings Report

    How Stryker Plans to Integrate Novadaq

    Overview On September 1, 2017, Stryker completed the acquisition of Novadaq Technologies. The company announced the deal on June 19, 2017. For details on the announcement, read Stryker Acquires Novadaq, Enhances Its Endoscopic Offerings. That day, Stryker’s stock price fell, and the iShares Core S&P 500 ETF (IVV) rose ~1.4%. SYK makes up ~0.23% of IVV’s […]

    By Sarah Collins
  • uploads///stock price
    Company & Industry Overviews

    Behind Intuitive Surgical’s Recent Stock Performance

    ISRG stock has been trending higher and was trading at its 52-week high of $382.2 on October 27, 2017. Its closing price on October 26 was $372.3.

    By Sarah Collins
  • uploads///recurring revenue model
    Company & Industry Overviews

    Why Intuitive Surgical Is Focusing on Imaging, Instruments, and Accessory Sales

    In 3Q17, Intuitive Surgical reported ~$401 million in instruments and accessories revenues. Recurring revenues contributed ~68% of total sales.

    By Sarah Collins
  • uploads///margins
    Company & Industry Overviews

    How Intuitive Surgical Reported Such High Margins in 3Q17

    Intuitive Surgical reported a gross profit margin of ~71.8% (of total sales) for 3Q17. This margin was lower, however, than the 73.1% it reported in 3Q16.

    By Sarah Collins
  • uploads///da vinci x
    Company & Industry Overviews

    How Intuitive Surgical Is Expanding Its Da Vinci X Systems Worldwide

    Intuitive Surgical’s (ISRG) Da Vinci X received early FDA approval in May 2017 and was given a CE Mark in Europe in April 2017.

    By Sarah Collins
  • uploads///system placement
    Company & Industry Overviews

    Why Intuitive Surgical’s Da Vinci System Placements Looks Lumpy outside the US

    In 3Q17, Intuitive Surgical (ISRG) registered system sales of ~$237 million, or ~15% higher on a YoY (year-over-year) basis.

    By Sarah Collins
  • uploads///REVENUE ESTIMATES
    Earnings Report

    Intuitive Surgical’s 3Q17 Revenue: Can It Beat the Estimates?

    According to recent Wall Street analysts’ estimates, Intuitive Surgical is expected to report revenues of $753.2 million in 3Q17. That represents a YoY sales growth of 10.3%.

    By Sarah Collins
  • uploads///installed base footprints
    Company & Industry Overviews

    Intuitive Surgical’s High Valuation: Is the Stock Overvalued?

    As of October 5, 2017, Intuitive Surgical’s (ISRG) forward PE (price-to-earnings) multiple is 120.3x, which is significantly higher than its peers and the industry average.

    By Sarah Collins
  • uploads///recommendations
    Company & Industry Overviews

    What Analysts Recommend for Intuitive Surgical

    According to the latest rating recommendations in a Reuters survey comprised of 18 brokerage companies, 61.0% of the firms gave ISRG a “buy” rating, and 33.0% rated it a “hold.”

    By Sarah Collins
  • uploads///stock price
    Company & Industry Overviews

    Intuitive Surgical Traded at a 52-Week High on October 5

    Intuitive Surgical (ISRG), the leader in minimally invasive robotics surgery, has seen tremendous growth lately. It was trading at its 52-week high of $1,094.55 on October 5, 2017.

    By Sarah Collins
  • uploads///recommendations
    Company & Industry Overviews

    Why Most Analysts Recommend a ‘Buy’ for Varian Medical Systems

    With its recent spin-off of Varex Imaging (VREX), Varian Medical Systems (VAR) has established itself as a focused cancer management medical technology company.

    By Sarah Collins
  • uploads///margin
    Company & Industry Overviews

    How Can BSX Improve Its Profitability Going Forward?

    In 2Q17, Boston Scientific registered a gross profit margin of 72.8% of its total sales. That compares to 70.7% in 2Q16.

    By Sarah Collins
  • uploads///recommendations
    Company & Industry Overviews

    Wall Street’s Upbeat on Boston Scientific: Most Recommend a ‘Buy’

    Wall Street analysts’ lowest one-year target price for Boston Scientific (BSX) stock is $24, representing a -11.4% maximum downside risk potential for the next year.

    By Sarah Collins
  • uploads///investments
    Company & Industry Overviews

    Strategic Investments Drive Intuitive Surgical’s Future Growth

    Intuitive Surgical focused on accelerating its strategic investments in recent years. It wants to expand across low-cost and untapped markets.

    By Sarah Collins
  • uploads///installed base footprints
    Company & Industry Overviews

    Intuitive Surgical Plans to Expand in Europe and Asia

    Although Intuitive Surgical leads the surgical robotics market, there are competitive threats from other major players in the market.

    By Sarah Collins
  • uploads///BUSINESS HIGHLIGHTS
    Company & Industry Overviews

    Analyzing Intuitive Surgical’s 2Q17 Results

    On July 20, 2017, Intuitive Surgical (ISRG) released its 2Q17 earnings results. The company revenues and earnings beat analysts’ estimates.

    By Sarah Collins
  • uploads///profitability drivers
    Company & Industry Overviews

    Why Varian Medical Systems’ Profitability Is Improving

    Varian Medical Systems’ profitability In 3Q17, Varian Medical Systems reported a gross margin of approximately 44.5%, representing an 18-basis-point improvement in the quarter. YTD (year-to-date), the margin has improved by around 138 basis points. In 3Q17, the company’s Oncology Systems business witnessed a gross margin improvement of 200 basis points to reach 48.1% of the segment’s total […]

    By Sarah Collins
  • uploads///analyst recommendations
    Company & Industry Overviews

    Analysts’ Recommendations for Varian Medical Systems

    With the spin-off of its Imaging Components business, Varian Medical Systems (VAR) is now more aligned with its core capabilities. In this series, we’ll discuss the company’s dynamics after the Varex spin-off.

    By Sarah Collins
  • uploads///CASH TREND
    Earnings Report

    How Intuitive Surgical Is Returning Value to Its Shareholders

    As of March 31, 2017, Intuitive Surgical has cash, cash equivalents, and investments of about $ 3.1 billion.

    By Sarah Collins
  • uploads///stock price
    Earnings Report

    What’s Driving Intuitive Surgical’s Recent Stock Performance?

    As of July 13, 2017, Intuitive Surgical’s stock was trading ~35.0% above its 52-week low of $610.7 on December 7, 2016.

    By Sarah Collins
  • uploads///REVEUE ESTIMATES
    Earnings Report

    Can Intuitive Surgical’s Revenue Grow in 2017?

    On July 20, 2017, Intuitive Surgical (ISRG) will announce its 2Q17 earnings. The company has exceeded analysts’ revenue estimates for the last several quarters.

    By Sarah Collins
  • uploads///eps estimates
    Earnings Report

    What to Expect from Intuitive Surgical’s 2Q17 Earnings

    Analysts estimate that Intuitive Surgical will post 2Q17 EPS (earnings per share) of ~$4.76. In 1Q17, Intuitive Surgical exceeded analysts’ diluted EPS estimate of $4.67.

    By Sarah Collins
  • uploads///recommendations
    Earnings Report

    What Wall Street Analysts Recommend for Intuitive Surgical

    Intuitive Surgical (ISRG) is set to release its 2Q17 results on July 20, 2017.

    By Sarah Collins
  • uploads///price history
    Company & Industry Overviews

    Will Intuitive Surgical Stock Witness Continued Growth Momentum?

    Intuitive Surgical (ISRG) has returned approximately 48.2% YTD (year-to-date), surpassing SPY as well as the Health Care Select Sector SPDR Fund (XLV) by enormous margins.

    By Sarah Collins
  • uploads///DA VINCI X
    Company & Industry Overviews

    ISRG Expands across Low-Cost Markets with Da Vinci X Launch

    On May 30, 2017, Intuitive Surgical (ISRG) announced that it received FDA (US Food and Drug Administration) approval of its new da Vinci X robotic surgical system.

    By Sarah Collins
  • uploads///DA VINCI SP
    Company & Industry Overviews

    Da Vinci Sp Could Boost ISRG Stock

    Intuitive Surgical’s da Vinci Sp is the latest technological innovation in the company’s surgical systems.

    By Sarah Collins
  • uploads///ma
    Company & Industry Overviews

    Zimmer Biomet’s Inorganic Growth Strategy Is Helping Performance

    In October 2016, Zimmer Biomet Holdings announced the acquisition of the RespondWell telerehabilitation platform.

    By Sarah Collins
  • uploads///mitg highlights
    Earnings Report

    What Drove Medtronic’s MITG Segment Growth?

    Medtronic (MDT) reported ~$7.9 billion in worldwide revenues in fiscal 4Q17.

    By Sarah Collins
  • uploads///PERFORMANCE
    Earnings Report

    Key Highlights of Varian Medical Systems’ Fiscal 2Q17 Earnings

    On April 26, 2016, Varian Medical Systems (VAR) released its 2Q17 earnings. VAR beat consensus estimates for revenues in 2Q17 by ~0.8% and reported in-line earnings per share.

    By Sarah Collins
  • uploads///CASH AND INVESTMENTS
    Earnings Report

    What’s Intuitive Surgical’s Capital Allocation Strategy?

    On December 13, 2016, Intuitive Surgical increased its authorized share repurchase program from $1.0 billion to $3.0 billion.

    By Sarah Collins
  • uploads///performance
    Earnings Report

    What to Expect from Intuitive Surgical’s 4Q16 Earnings

    Intuitive Surgical expects about a 15.0% procedure growth in fiscal 2016, which is expected to boost the company’s earnings.

    By Sarah Collins
  • uploads///MITG
    Earnings Report

    Here’s What’s Driving Medtronic’s MITG Segment

    Of Medtronic’s ~$7.3 billion in worldwide revenues in fiscal 2Q17, ~$2.5 billion came from Medtronic’s MITG segment, representing ~34% of the company’s total revenues.

    By Sarah Collins
  • uploads///mako
    Company & Industry Overviews

    Exploring SYK’s MAKO Robot Performance and Future Expectations

    Stryker (SYK) has identified its need to differentiate its offerings in the competitive orthopedics market, which has undergone business model changes.

    By Sarah Collins
  • uploads///particle
    Earnings Report

    Particle Therapy Business Witnessed Continued Growth Momentum in 4Q16

    Varian Medical Systems (VAR) registered revenues of $68.2 million in 4Q16, of which 7.5% came from the company’s oncology segment.

    By Sarah Collins
  • uploads///q trends
    Earnings Report

    What Are the Key Drivers of Intuitive Surgical’s 3Q16 Growth?

    Intuitive Surgical registered a YoY procedure growth of ~14% in 2Q16. Sales from da Vinci System outside the US also witnessed considerable growth.

    By Sarah Collins
  • uploads///IFF
    Basic Materials

    International Flavors and Fragrances to Acquire David Michael

    On September 13, International Flavors and Fragrances (IFF) announced that it entered into an agreement to acquire food flavor company David Michael.

    By Peter Neil
  • uploads///Portfolio Breakdown of the PLGAX
    Fund Managers

    Sector Composition of Principal LargeCap Growth Fund I in YTD 2016

    Information technology is the largest invested sector by the Principal LargeCap Growth Fund I (PLGAX), comprising a little less than one-third of the portfolio.

    By David Ashworth
  • uploads///oncology
    Company & Industry Overviews

    Varian Medical Systems’ Oncology Devices Are Key to Sales Growth

    Varian Medical Systems commands the majority share of the oncology device market in the United States.

    By Sarah Collins
  • uploads///surgery trends
    Company & Industry Overviews

    Hernia Repair Should Drive Significant Growth for Intuitive Surgical

    The benefits of robotic-assisted ventral hernia repair surgery were substantiated by study results released by Intuitive Surgical (ISRG) in early August 2016.

    By Sarah Collins
  • uploads///forward pe
    Company & Industry Overviews

    A Look at Zimmer Biomet’s Latest Valuation

    After the release of its 2Q16 earnings results on July 28, 2016, Zimmer Biomet Holdings (ZBH) was trading at a forward price-to-earnings multiple in the range of 15.5x–16.2x.

    By Sarah Collins
  • uploads///ldr
    Company & Industry Overviews

    Zimmer Biomet Focuses on Inorganic Growth Strategy

    In July 2016, Zimmer Biomet completed the tender offer for outstanding shares of LDR Holding Corporation for $37 per share.

    By Sarah Collins
  • uploads///revenue
    Earnings Report

    2Q16 Revenue Estimates for Intuitive Surgical

    On July 19, 2016, Intuitive Surgical (ISRG) will announce its 2Q16 earnings. Wall Street has estimated the company’s 2Q16 revenues will come in at ~$640 million.

    By Sarah Collins
  • uploads///analyst recommendations
    Earnings Report

    Analysts’ Latest Recommendations for Intuitive Surgical

    The consensus 12-month target price for Intuitive Surgical (ISRG) is $684.50, which represents a potential rise of ~1.3%.

    By Sarah Collins
  • uploads///product innovation
    Company & Industry Overviews

    How Has Varian Medical Systems Progressed in Radiotherapy?

    Varian Medical Systems (VAR) has an innovation-led product pipeline.

    By Sarah Collins
  • uploads///valuation
    Company & Industry Overviews

    How Does Varian Medical Systems Compare to Peers on Valuation?

    On June 16, 2016, Varian Medical Systems (VAR) was trading at a forward PE (price-to-earnings) ratio of ~17.7x.

    By Sarah Collins
  • uploads///growth strategy
    Company & Industry Overviews

    Growth Strategies Driving Varian Medical Systems’ Revenue

    Varian Medical Systems has ventured into the proton therapy business and has a huge product pipeline in this area. The company generated approximately $300 million through its proton therapy business in 2015.

    By Sarah Collins
  • uploads///business segments
    Company & Industry Overviews

    Where Does Varian Medical Systems Get Most of Its Revenue?

    Varian Medical Systems’ Imaging Components segment accounts for approximately 19% of the company’s total revenue. The segment reported a revenue decline of ~10% in 2015.

    By Sarah Collins
  • uploads///renaissance
    Company & Industry Overviews

    Medtronic: The New Entrant into the Robotic Surgery Business

    Medtronic (MDT) is set to enter the robotic surgery market through a partnership with Mazor Robotics, an Israeli company. Mazor Robotics the Renaissance Guidance System used in spinal surgeries.

    By Sarah Collins
  • uploads///Portfolio Breakdown of the PLGAX
    Fund Managers

    How PLGAX’s Portfolio Has Changed

    The Principal LargeCap Growth Fund I Class A (PLGAX) invests at least 80% of its assets in equities of large-capitalization companies.

    By David Ashworth
  • uploads///Part  Graph
    Company & Industry Overviews

    Boston Scientific to Present at Goldman Sachs Healthcare Conference

    Boston Scientific (BSX) was the biggest gainer among the large caps of the iShares U.S. Medical Devices ETF (IHI).

    By Peter Neil
  • uploads///stock performance
    Company & Industry Overviews

    How Has Intuitive Surgical’s Stock Price Been Performing?

    Intuitive Surgical (ISRG) was trading at $621.4 as of May 17, 2016. It has a 50-day moving average of $623.9 and a 200-day moving average of $562.8.

    By Sarah Collins
  • uploads///RD expenses
    Company & Industry Overviews

    Analyzing Intuitive Surgical’s R&D Strategy and Innovations

    Intuitive Surgical is continuously enhancing its product offerings, enabling more efficient procedures through internal research and development (or R&D).

    By Sarah Collins
  • uploads///revenues by geography
    Company & Industry Overviews

    Understanding Intuitive Surgical’s Geographical Profile

    Intuitive Surgical (ISRG) has established geographical growth as one its major growth drivers after procedure growth.

    By Sarah Collins
  • uploads///open surgery trends
    Company & Industry Overviews

    A Closer Look at Intuitive Surgical’s Business Strategy

    Intuitive Surgical aims to include a larger patient population under its MIS treatments and to provide better surgery outcomes and lower recovery times.

    By Sarah Collins
  • uploads///installed base
    Company & Industry Overviews

    Exploring Intuitive Surgical’s Sales Model

    Intuitive Surgical follows a diversified sales strategy and doesn’t generate more than 10% of its revenue through any one customer.

    By Sarah Collins
  • uploads///procedure trends
    Company & Industry Overviews

    How Is Procedure Growth Driving Intuitive Surgical’s Revenue?

    The number of procedures performed using Intuitive Surgical’s da Vinci surgical system in 1Q16 rose by around 17% year-over-year.

    By Sarah Collins
  • uploads///recurring revenue model
    Company & Industry Overviews

    What Does Intuitive Surgical’s Business Model Look Like?

    Intuitive Surgical (ISRG) defines its business model as a “razor/razor blade” model. What does this mean?

    By Sarah Collins
  • uploads///product profile
    Company & Industry Overviews

    Delving into the Nuances of the Da Vinci Surgical System

    The da Vinci surgical system provides the benefits of minimally invasive surgery along with the precision and control of open surgery.

    By Sarah Collins
  • uploads///ISRGs history timeline
    Company & Industry Overviews

    Company Overview: An Introduction to Intuitive Surgical

    Intuitive Surgical is a pioneer of minimally invasive robotic surgery. It develops and manufactures da Vinci surgical systems and related instruments.

    By Sarah Collins
  • uploads///Sectoral Allocation of the PLGAX
    Fund Managers

    A Quick Look at the Principal LargeCap Growth Fund I

    The Principal LargeCap Growth Fund I (PLGAX) invests at least 80% of its assets in equities of large-cap companies.

    By David Ashworth
  • uploads///Part  Graph
    Company & Industry Overviews

    How Has Medical Device ETF IHI Performed?

    The iShares US Medical Device ETF (IHI) has remained stable and has outperformed other healthcare and biotechnology ETFs in 2016.

    By Peter Neil
  • uploads///key components of Reimbursement
    Company & Industry Overviews

    How Reimbursement Models Impact the Medical Device Industry

    Coverage, coding, and payment are essential elements to obtaining adequate reimbursement for a new medical device.

    By Sarah Collins
  • uploads///Graph Part  Oct
    Company & Industry Overviews

    How Celgene Reacted to Positive Clinical Trials on October 26, 2015

    Celgene rose by 2.95% and closed at $123.65, surpassing its 50- and 100-day moving average prices of $118.45 and $121.09.

    By Peter Neil
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.